share_log

微創醫療：海外監管公告

MICROPORT: Overseas Regulatory Notice

HKEX ·  Aug 26 09:04

Summary by Moomoo AI

醫療器械公司MICROPORT於2024年8月26日披露了其2024年中期報告，該報告涵蓋了財務表現和企業活動。MICROPORT持有上海微創心血管科技（集團）有限公司（簡稱「Endovastec」）40.32%的股本，Endovastec在上海證券交易所科創板上市，其業績已納入MICROPORT的財務結果。該公告符合香港上市規則13.10B，確保香港投資者獲得等同信息。公司執行董事包括張朝華博士，非執行董事有白騰泰先生、盧天元先生、孫維勤女士，以及獨立非執行董事周家鴻先生、劉國恩博士和邵春陽先生。Endovastec的2024年中期報告強調了對準確報告的承諾，董事會和監事會確保報告的真實性、...展開全部
醫療器械公司MICROPORT於2024年8月26日披露了其2024年中期報告，該報告涵蓋了財務表現和企業活動。MICROPORT持有上海微創心血管科技（集團）有限公司（簡稱「Endovastec」）40.32%的股本，Endovastec在上海證券交易所科創板上市，其業績已納入MICROPORT的財務結果。該公告符合香港上市規則13.10B，確保香港投資者獲得等同信息。公司執行董事包括張朝華博士，非執行董事有白騰泰先生、盧天元先生、孫維勤女士，以及獨立非執行董事周家鴻先生、劉國恩博士和邵春陽先生。Endovastec的2024年中期報告強調了對準確報告的承諾，董事會和監事會確保報告的真實性、準確性和完整性。報告為未經審計。Endovastec提出2024年上半年的利潤分配計劃，建議每10股派發現金紅利人民幣16.50元，總計人民幣203,382,493.05元，佔2024年1月至6月歸屬於股東的淨利潤的50.40%。該利潤分配計劃需經董事會和2024年第三次臨時股東大會批准。報告中的前瞻性聲明不構成對投資者的實質承諾，投資者應謹慎行事，注意投資風險。報告包含了詳細的財務數據、管理層討論與分析、公司治理、環境與社會責任、重大事項、股東變動及其他相關披露。
Medical instruments company MICROPORT disclosed its 2024 interim report on August 26, 2024, covering financial performance and corporate activities. MICROPORT holds 40.32% of the shares in Shanghai MicroPort CardioFlow Endovascular Technology (Group) Co., Ltd. (referred to as 'Endovastec'). Endovastec is listed on the Star Market of the Shanghai Stock Exchange, and its performance is included in MICROPORT's financial results. This announcement complies with Rule 13.10B of the Hong Kong Listing Rules to ensure that Hong Kong investors receive equivalent information. The company's executive directors include Dr. Zhang Chaohua, non-executive directors Mr. Bai Tengtai, Mr. Lu Tianyuan, Ms. Sun Weiqin, and independent non-executive directors Mr. Zhou Jiahong, Dr. Liu Guoen, and Mr. Shao Chunyang. Endovastec's 2024 interim report emphasizes the commitment to...Show More
Medical instruments company MICROPORT disclosed its 2024 interim report on August 26, 2024, covering financial performance and corporate activities. MICROPORT holds 40.32% of the shares in Shanghai MicroPort CardioFlow Endovascular Technology (Group) Co., Ltd. (referred to as 'Endovastec'). Endovastec is listed on the Star Market of the Shanghai Stock Exchange, and its performance is included in MICROPORT's financial results. This announcement complies with Rule 13.10B of the Hong Kong Listing Rules to ensure that Hong Kong investors receive equivalent information. The company's executive directors include Dr. Zhang Chaohua, non-executive directors Mr. Bai Tengtai, Mr. Lu Tianyuan, Ms. Sun Weiqin, and independent non-executive directors Mr. Zhou Jiahong, Dr. Liu Guoen, and Mr. Shao Chunyang. Endovastec's 2024 interim report emphasizes the commitment to accurate reporting, with the board of directors and board of supervisors ensuring the truthfulness, accuracy, and completeness of the report. The report is unaudited. Endovastec has proposed a profit distribution plan for the first half of 2024, recommending a cash dividend of RMB 16.50 for every 10 shares, totaling RMB 203,382,493.05, accounting for 50.40% of the net profit attributable to shareholders from January to June 2024. This profit distribution plan is subject to approval by the board of directors and the third extraordinary general meeting of shareholders in 2024. Forward-looking statements in the report do not constitute a substantial commitment to investors, who should exercise caution and be aware of investment risks. The report includes detailed financial data, management discussion and analysis, corporate governance, environmental and social responsibility, significant matters, changes in shareholders, and other relevant disclosures.

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated